AXS-12

AXS-12 (reboxetine) is a novel, oral, investigational medicine in development for the treatment of the symptoms of narcolepsy. AXS-12 is a highly selective and potent norepinephrine reuptake inhibitor. AXS-12 is an investigational drug not approved by the FDA.

An New Therapeutic Approach

How It Works
AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor. Reboxetine has an extensive safety record in Europe and in over 40 countries where it is approved for the treatment of Depression. AXS-12 in narcolepsy is supported by positive pre-clinical and preliminary clinical results where it significantly reduced narcoleptic episodes in hypocretin (orexin)-deficient mice as well as improving daytime sleepiness with reduced cataplexy in patients with narcolepsy in an open-label pilot trial.

TRD CLINICAL TRIAL

STRIDE-1 Study

AXS-05 is being evaluated in the STRIDE-1 (Symptom Treatment in Resistant Depression 1) study. STRIDE-1 is a Phase 3 multicenter, randomized, double-blind, active-controlled trial designed to evaluate the efficacy and safety of AXS-05 in the treatment of treatment resistant depression (TRD).

AD AGITATION CLINICAL TRIAL

ADVANCE-1 Study

AXS-05 is being evaluated in the ADVANCE-1 (Addressing Dementia Via Agitation-Centered Evaluation 1) study. ADVANCE-1 is a Phase 2/3 multicenter, randomized, double-blind, controlled trial to evaluate the efficacy and safety of AXS-05 in patients with agitation associated with Alzheimer’s disease.

Knee OA Clinical Trial

COAST-1 Study

AXS-02 is being evaluated in the COAST-1 (Clinical Knee Osteoarthritis Symptom Treatment 1). COAST-1 is a Phase 3 multinational, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of AXS-02 for the treatment of the pain of knee OA associated with BMLs.